Penumbra, Inc. (NYSE:PEN) is a prominent player in the medical instruments industry, particularly known for its thrombectomy products. The company has shown strong financial performance, as evidenced by its recent earnings report. On February 26, 2026, Priya Sachdeva from UBS set a price target of $374 for PEN, suggesting a potential increase of about 9.92% from its current trading price of $340.24.
Penumbra's recent quarterly earnings of $1.18 per share exceeded the Zacks Consensus Estimate of $1.12, marking a 5.36% earnings surprise. This is a significant improvement from the $0.97 per share reported a year ago. The company has consistently outperformed consensus EPS estimates over the past four quarters, demonstrating its strong financial health and operational efficiency.
In addition to strong earnings, Penumbra reported revenues of $385.39 million for the quarter ending December 2025, surpassing the Zacks Consensus Estimate by 6.74%. This represents a 22.1% increase from the $315.52 million reported for the same period last year. The company's consistent performance in exceeding revenue estimates highlights its robust growth trajectory.
The United States accounted for 77.6% of Penumbra's total revenue, with international markets contributing 22.4% during the fourth quarter of 2025. U.S. revenue increased by 20.6%, while international revenue surged by 27.7%. Sales of Penumbra's global thrombectomy products rose to $254.7 million, driven by strong U.S. sales.
Currently, PEN is priced at $341.11, reflecting a 0.72% increase. The stock has fluctuated between $338.82 and $341.12 today, with a market capitalization of approximately $13.38 billion. Over the past year, PEN has reached a high of $362.41 and a low of $221.26, indicating its dynamic market presence.
